| CASE REPORT |
|
| Year : 2022 | Volume
: 13
| Issue : 3 | Page : 247-250 |
|
|
Leydig cell hyperplasia of ovary – An unusual finding in postneoadjuvant chemotherapy case of primary fallopian tube carcinoma
Kriti Chaturvedi1, Meenakshi Rao1, Souvik Saha1, Jeewan Ram Vishnoi2, Aasma Nalwa1
1 Department of Pathology and Lab Medicine, AIIMS, Jodhpur, Rajasthan, India
2 Department of Surgical Oncology, AIIMS, Jodhpur, Rajasthan, India
Correspondence Address:
Meenakshi Rao
Department of Pathology, AIIMS, Jodhpur, Rajasthan
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmh.jmh_117_22
|
|
|
A large number of high-grade serous ovarian carcinomas originate in the fallopian tubes. Neoadjuvant chemotherapy followed by surgery may lead to a number of chemotherapy-induced changes in the ovary, which may lead to an erroneous diagnosis. We present a rare case of a 55-year-old postmenopausal woman who was clinically diagnosed with carcinoma of the right ovary; on histopathologic evaluation after neoadjuvant chemotherapy, the primary site was found to be the right fallopian tube. The right ovary showed chemotherapy-related changes along with extensive Leydig cell hyperplasia. As the presence of Leydig cell hyperplasia in this setting is an unusual finding, it may pose a diagnostic dilemma for the pathologist; so an awareness of this entity is important to avoid misdiagnosis.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
